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TNFAIP3 Gene Polymorphisms Are Associated with
Response to TNF Blockade in Psoriasis
Trilokraj Tejasvi1, Philip E. Stuart1, Vinod Chandran2, John J. Voorhees1, Dafna D. Gladman2,
Proton Rahman3, James T. Elder1,4 and Rajan P. Nair1
The tumor necrosis factor-alpha–induced protein 3 (TNFAIP3) gene has been associated with psoriasis,
rheumatoid arthritis, type 1 diabetes mellitus, systemic lupus erythematosus, and celiac disease. TNFAIP3
encodes A20, a tumor necrosis factor (TNF)-a–inducible zinc finger protein thought to limit NF-kB–mediated
immune responses. In this study, we report association of response of psoriasis to TNF blockers with two
TNFAIP3 single-nucleotide polymorphisms (rs2230926 in exon 7 and rs610604 in intron 3) and their haplotypes.
Treatment response was self-evaluated using a 0–5 visual analog scale in 433 psoriasis patients who received
TNF blockers. Confirmation was sought in 199 psoriasis and psoriatic arthritis patients from Toronto who were
followed up prospectively. Response variables were dichotomized separately in the two cohorts, yielding
similar proportions of good responses. Whereas significant associations were observed only for the Michigan
cohort, fixed-effects meta-analysis retained significant association between dosage of the G allele of rs610604
and good combined response to all TNF blockers (odds ratio (OR)¼ 1.50, Pcorr¼ 0.050) and etanercept
(OR¼ 1.64, Pcorr¼ 0.016). The rs2230926 T-rs610604 G haplotype was similarly associated. By demonstrating an
association with therapeutic response, these results provide a clinically relevant functional correlate to the
recently described genetic association between psoriasis and TNFAIP3.
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INTRODUCTION
Psoriasis is a common immune-mediated disorder of the skin,
nails, scalp, and joints, with a multifactorial genetic basis.
Recent association studies have identified 25 susceptibility
loci reaching genome-wide significance for psoriasis
(Nair et al., 2009; Ellinghaus et al., 2010; Huffmeier et al.,
2010; Strange et al., 2010; Stuart et al., 2010; Sun et al.,
2010). The HLA-C region on chromosome 6p21.3 emerged
as the strongest associated locus in all populations studied,
accompanied by several genes involved in the immune and
inflammatory pathways (Elder et al., 2010). Biological drugs
targeting tumor necrosis factor-a (TNF-a, encoded by the
TNF gene, which happens to be located 303 kb centromeric
of HLA-C) have been highly successful in treating severe
psoriasis vulgaris (PsV), as well as the subset ofB25% of PsV
patients (Gottlieb et al., 2003; Leonardi et al., 2003; Papp
et al., 2005) diagnosed with psoriatic arthritis (PsA). Never-
theless, there is marked heterogeneity in treatment response
to these medications. Multiple studies evaluating the anti-
psoriatic efficacy of anti-TNF agents have demonstrated
efficacy of X75% reduction in Psoriasis Area Severity Index
(PASI, a composite score that measures erythema, induration,
and scaling weighted for the body surface involved) in
45–70% patients depending on the dosage and duration of
treatment (Sobell et al., 2009).
Compared with traditional systemic therapies for psoriasis,
such as phototherapy and methotrexate, treatment with the
anti-TNF drugs poses a considerable financial burden. A year
of biologic therapy can cost between US $10,000 and $25,000
based on the dosage and treatment regimen prescribed
(Cordoro and Feldman, 2007), whereas methotrexate and
narrow-band UVB phototherapy would cost $623 and $3,692,
respectively (Pearce et al., 2006). Given these costs, accurate
predictors of therapeutic response to anti-TNF agents would be
of great value in making decisions on treatment options.
Previous studies addressing genetic predictors of thera-
peutic response have investigated promoter region poly-
morphisms in the TNF gene in rheumatoid arthritis (RA),
ankylosing spondylitis, Crohn’s disease, and ulcerative colitis
(Pierik et al., 2006; Kooloos et al., 2007; Seitz et al., 2007;
Maxwell et al., 2008; Musone et al., 2008; O’Rielly et al.,
2009). We carried out a survey-based evaluation of TNF
promoter region polymorphisms in 343 psoriasis patients
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treated with TNF antagonists, and found an association with
the TNF-238 G/A polymorphism (odds ratio (OR)¼ 2.03,
P¼0.044; Tejasvi et al., 2008). However, this association was
only nominally significant, prompting evaluation of additional
patients, as well as additional potential genetic loci.
Tumor necrosis factor-alpha–induced protein 3 (TNFAIP3)
was originally identified as a TNF-inducible gene, which, at
least in some settings, functions as a negative feedback
inhibitor of TNF signaling (Opipari et al., 1990; Werner et al.,
2008). Recent genome-wide association studies (GWAS)
have revealed associations between TNFAIP3 and psoriasis
(Nair et al., 2009; Strange et al., 2010), RA (Plenge et al.,
2007; Thomson et al., 2007), type 1 diabetes mellitus (Fung
et al., 2009), systemic lupus erythematosus (Graham et al.,
2008), celiac disease (Trynka et al., 2009), and chronic
sinusitis (Cormier et al., 2009). Its protein product, A20,
functions as a dual enzyme: initially it removes Lys63-linked
ubiquitin chains from RIP1, an essential mediator of the
proximal TNFR signaling complex. Later, it functions as E3
ligase, leading to polyubiquitinylation of RIP1 via Lys48 that
targets RIP1 for proteasomal degradation, resulting in
termination of TNF-induced NF-kB signaling (Wertz et al.,
2004; Liu et al., 2005). A20 can also remove K63-linked
polyubiquitin chains from TRAF6 and RIP2, inhibiting NF-kB
activation by TLR4 and NOD2, respectively (Vereecke et al.,
2009). A20 also blocks NF-kB activation induced by TAK1
overexpression, which signals downstream of RIP1, RIP2, and
TRAF6 (Zetoune et al., 2001). It can also target TRAF2 for
lysosomal degradation, independent of its ubiquitin modify-
ing properties (Li et al., 2009). Thus, A20 acts at multiple
steps in the NF-kB signaling pathway (Vereecke et al., 2009).
A20 binds to ABIN-1 (A20 binding inhibitor of NF-kB), a
protein encoded by the TNIP1 gene, which, interestingly, is
also associated with psoriasis (Nair et al., 2009) and systemic
lupus erythematosus (Gateva et al., 2009; Han et al., 2009).
This interaction also temporally limits NF-kB activation
(Heyninck et al., 1999), at least in part by binding of ABIN-1
to NEMO (NF-kB essential modulator)/IKK-g (NF-kB Kinase
subunit gamma) (Mauro et al., 2006).
In a GWAS of response to TNF blockers in RA, 89 patients
were analyzed using 283,348 single-nucleotide polymorph-
isms (SNPs), yielding nine signals reaching nominal signifi-
cance (Po0.05; Liu et al., 2008). In a very recent GWAS, a
total of 1,286 anti-TNF–treated patients were analyzed in a
three-stage design (Plant et al., 2011). No loci yielded statistical
evidence reaching genome-wide significance, emphasizing the
need for much larger cohorts for unbiased estimation of
pharmacogenetic responses to TNF antagonists and indeed to
other biologics and immunomodulators in general.
A recent pharmacogenomic study looking into the profile
of early gene expression among responders and nonrespond-
ers to anti-TNF therapy in RA revealed early downregulation
of expression of TNFAIP3 mRNA levels secondary to TNF
neutralization in responders (Koczan et al., 2008). However,
to date, there are no published pharmacogenetic studies of
the relationship between the TNFAIP3 locus and responsive-
ness to anti-TNF agents in psoriasis. In this study, we evaluate
the role of two polymorphisms in the TNFAIP3 gene as
predictors of clinical response to TNF blockade in patients
with psoriasis and/or PsA from two study sites.
RESULTS
We studied 433 psoriasis patients from Michigan and 199
patients from Toronto who received treatment with any
of three different TNF blockers—etanercept, infliximab, and
adalimumab. We compared the two samples for 19 demo-
graphic and phenotypic variables (Table 1). Highly significant
differences were observed between the means of three
variables—the Toronto sample had more PsA patients
(93.0% vs. 58.3%, P¼ 2.91020), whereas the Michigan
sample had a higher mean age (51.4 vs. 46.0 years,
P¼8.6107) and a higher percentage of patients with a
family history of psoriasis (60.6% vs. 42.9%, P¼ 4.5105).
The Michigan sample also had a later age at PsA onset (37.6
vs. 33.6 years, P¼ 0.0028). A nominally significant difference
(P¼0.019) in the percentage of patients with inflammatory
bowel disease did not remain so after correction for multiple
testing. No significant difference between the two samples
was seen in the percentage of good response to treat-
ment with any of the anti-TNF agents, either individually or
combined. Furthermore, the frequencies of the allele impart-
ing risk for psoriasis did not differ significantly between the
two groups for either of the two analyzed TNFAIP3 SNPs.
Covariate analyses with age at onset, body mass index
(BMI), and the presence of PsA were performed in both
cohorts, along with worst-ever total body surface area in the
Michigan cohort. Age at onset was significantly and negatively
associated with response to TNF blockers in the Michigan
cohort (OR¼ 0.973, P¼0.00016). Although not reaching
nominal significance, age at onset also trended toward nega-
tive association with all anti-TNF responses in the Toronto
sample (OR¼0.982 for all TNF blockers combined).
Data were analyzed for linear trend of association bet-
ween drug response and genotypes and haplotypes of one
disease-associated SNP in intron 3 (rs610604, minor allele
frequency¼ 0.338; Nair et al., 2009) and another in exon 7
of TNFAIP3 (rs2230926, minor allele frequency¼0.029).
The latter was the only tested exonic SNP that was
polymorphic in our sample. In the Michigan sample,
association was observed between dosage of the G allele of
rs610604 and good response to all TNF blockers (OR¼1.74,
Pnom¼0.0027, Pcorr¼0.0084; Table 2). Combined analysis
of the two samples using a fixed-effects model showed
association between dosage of the G allele of rs610604 and
good response to all TNF blockers combined (OR¼1.50,
Pnom¼0.010, Pcorr¼0.050). Despite a similar OR, this
association was no longer significant when the combined
analysis used a random-effects model (OR¼1.39,
Pnom¼0.22, Pcorr¼ 0.77; Table 2). Age at onset of disease
was included as a covariate in all association models, and the
nested logistic regression models testing association for each
combination of SNP and drug revealed that the associations
of age at onset and SNP rs610604 with drug response were
independent of each other (no significant interaction).
Haplotype analysis (Table 3) revealed that dosage of
the rs2230926 T-rs610604 G haplotype was associated with
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good response to all TNF blockers (OR¼ 1.82, Pnom¼
0.0012, Pcorr¼ 0.0060) in the Michigan cohort. Combined
analysis of both groups under a fixed-effects model showed
association between the rs2230926 T-rs610604 G haplotype
and response to all TNF blockers (OR¼1.55, Pnom¼0.0051,
Pcorr¼0.031). The association of haplotype rs2230926
T-rs610604 G with response to TNF blockers in the Michigan
cohort is driven mainly by rs610604; conditional haplo-
type testing showed that the independent contribution of the
rs610604 G allele to the association is significant
(Pnom¼0.0016), whereas the independent contribution of
the rs2230926 T allele is not (Pnom¼0.90).
DISCUSSION
The TNFAIP3 gene has been shown to be associated with
psoriasis in a recent GWAS (Nair et al., 2009), a finding
recently confirmed strongly in Caucasian (Strange et al.,
2010) and suggestively in Chinese (Sun et al., 2010)
populations. Here we demonstrate that polymorphisms in
TNFAIP3 are associated with response to anti-TNF agents in
psoriasis patients. In the Michigan sample, good response to
etanercept alone and all TNF blockers combined was
positively associated with dosage of the G allele of
rs610604, a psoriasis susceptibility allele (Nair et al., 2009).
The proportion of good responders to anti-TNF treatment was
substantially larger for people carrying two copies of this
allele compared with carriers of no copies, both for
etanercept (90.7% vs. 70.3%, P¼0.0027) and for all TNF
blockers combined (88.%1 vs. 70.7%, P¼ 0.0075). To a
lesser degree, the same holds true for heterozygous carriers of
the G risk allele compared with noncarriers (79.1% vs.
70.3%, P¼0.067 for etanercept and 80.1% vs. 70.7%,
P¼0.034 for all TNF blockers). We also found an association
of haplotype rs2230926 T-rs610604 G with good response
to etanercept or all TNF blockers (Table 3).
Here, we also report significant association between age at
onset and treatment response that is independent of TNFAIP3
genotype; a later age at onset is associated with poorer
response to treatment. The profile of genetic risk factors,
especially the role of HLA-Cw6, differs between early- and
late-onset psoriasis (Gudjonsson et al., 2002; Chen et al.,
2011), which may influence the effectiveness of TNF
blockers. The use of phenotypes as predictors of response
to anti-TNF agents in RA showed that age of the patient was
not associated with treatment response (Eder et al., 2010),
and in ankylosing spondylitis age was negatively associated
with response to treatment (Arends et al., 2011). As we did
not collect age at treatment data, a direct comparison was not
possible. Other covariates analyzed did not show any
association with treatment response.
Table 1. Phenotypic comparison of Michigan and Toronto samples
Michigan sample Toronto sample
Variable (unit) n1 Mean SD n1 Mean SD P-value2
Age at study entry (years) 433 51.4 13.9 199 46.0 12.0 8.6 107
Age at PsV onset (years) 433 26.9 15.5 196 26.2 13.7 0.75
Duration of psoriasis (years) 433 24.4 15.6 196 19.7 12.4 0.055
Age at PsA onset (years) 214 37.6 13.6 185 33.6 12.6 0.0028
Duration of PsA (years) 214 14.8 12.3 185 12.3 9.3 0.61
BMI (kgm2) 431 30.5 7.2 192 29.1 5.9 0.10
Males (%) 433 43.2 2.4 199 38.7 3.5 0.30
PsA (%) 376 58.3 2.6 199 93.0 1.8 2.9 1020
Nail involvement (%) 417 79.4 2.0 199 84.4 2.6 0.15
IBD (%) 405 3.2 0.9 199 2.0 1.0 0.60
Autoimmune disease (%) 402 5.7 1.2 197 4.6 1.5 0.70
Family history of PsV (%) 419 60.6 2.4 198 42.9 3.5 4.5 105
Family history of IBD (%) 415 11.8 1.6 194 5.7 1.7 0.019
rs610604 G allele frequency (%) 432 37.5 1.6 188 38.6 2.5 0.75
rs2230926 T allele frequency (%) 430 97.1 0.6 188 96.8 0.9 0.86
Good etanercept response (%) 380 77.4 2.1 139 83.5 3.2 0.15
Good adalimumab response (%) 89 77.5 4.4 31 74.2 7.0 0.81
Good infliximab response (%) 89 80.9 4.2 29 82.8 4.2 1.00
Good TNF blocker response (%) 433 77.6 2.0 199 81.9 2.7 0.25
Abbreviations: BMI, body mass index; IBD, irritable bowel disease; PsA, psoriatic arthritis; PsV, psoriasis vulgaris; TNF, tumor necrosis factor.
1Number of non-missing observations.
2Nominal P-value for the test of the equality of the variable means for the Michigan and Toronto samples. Tests for duration of PsV, duration of PsA, and BMI
were adjusted for the effects of age. See Materials and Methods for details of testing procedure.
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We did not find any association of drug response
and TNFAIP3 genotype in the Toronto replication sample.
This outcome could be due to limited power. For the
strongest effect observed in the Michigan sample
(OR¼1.83 for etanercept response and G allele dosage at
rs6010604), the Toronto sample has only 43% power
to detect association at a nominal significance level of
0.05 and 29% power when significance is corrected for
multiple testing. Because of the winner’s curse (Goring et al.,
2001), the estimated effect size in the Michigan sample
is likely biased upward, and power for a more realistic OR
of 1.50 (midway between 1.83 and the lower bound of its
corrected 95% confidence interval) is only 22% and 13%
at a nominal and corrected significance level of 0.05,
respectively. To achieve 80% power to detect an OR of
1.83 at a nominal or corrected significance of 0.05, sample
size for the Toronto cohort would need to be increased
2.5- or 3.2-fold; for an OR of 1.50, 80% power requires 5.5-
or 6.9-fold increases in sample size.
The lack of association in the Toronto sample could also
be due to heterogeneity; i.e., response to anti-TNF drugs is
genuinely more poorly associated with TNFAIP3 genotype
in the Toronto population than in the Michigan population.
The estimated I2 coefficient of heterogeneity for asso-
ciation, of both etanercept response and combined TNF
blocker response with r610604 genotype, is greater than zero
(I2¼ 27.5 and 54.3%, respectively), leading to a reduced
significance of the combined analysis for these two associa-
tions when using a random-effects model versus fixed-effects
model (Table 2). However, neither of these I2 coefficients
is significant (95% confidence interval¼ 0.0–72.0% and
0.0–88.8%, respectively), nor is the related Cochran’s Q-test
of heterogeneity (P¼ 0.24 and 0.14, respectively). It is
important to note that these results are inconclusive, as the
Table 2. Association of genotypes for two TNFAIP3 SNPs with a combined skin–joint response to TNF blockers for
psoriasis patients in the Michigan, Toronto, and combined samples
Michigan
sample
Toronto
sample
Combined analysis
(fixed/random effects)
SNP Drug Genotype
Good
response1
Poor
response1 OR2 P-value3
Good
response1
Poor
response1 OR2 P-value3 OR2 P-value3
rs2230926 Etanercept TT 275 (0.945) 79 (0.919) 1.77 0.19 (0.74) 101 (0.927) 19 (0.950) 0.63 0.67 (0.99) 1.53/1.53 0.30/0.30 (0.92/0.89)
TG 16 (0.055) 6 (0.070) 8 (0.073) 1 (0.050)
GG 0 (0.000) 1 (0.011) 0 (0.000) 0 (0.000)
Adalimumab TT 54 (0.915) 28 (0.933) 0.66 0.64 (1.00) 20 (0.952) 5 (0.833) 2.39 0.59 (0.98) 1.12/1.12 0.89/0.89 (1.00/1.00)
TG 5 (0.085) 2 (0.067) 1 (0.048) 1 (0.167)
GG 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000)
Infliximab TT 69 (0.958) 15 (0.882) 3.00 0.26 (0.92) 23 (0.958) 5 (1.00) 0.00 1.00 (1.00) 3.00/3.00 0.26/0.26 (0.89/0.86)
TG 3 (0.042) 2 (0.118) 1 (0.042) 0 (0.000)
GG 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000)
Combined TT 315 (0.956) 91 (0.944) 1.40 0.45 (0.98) 144 (0.935) 29 (0.935) 0.90 0.89 (1.00) 1.26/1.26 0.55/0.55 (0.99/0.99)
TG 18 (0.044) 5 (0.037) 10 (0.065) 2 (0.065)
GG 0 (0.020) 1 (0.019) 0 (0.000) 0 (0.000)
rs610604 Etanercept GG 49 (0.167) 5 (0.058) 1.83 0.0020 (0.0068) 14 (0.128) 2 (0.100) 1.10 0.79 (1.00) 1.64/1.57 0.0043/0.051 (0.016/0.31)
GT 140 (0.478) 37 (0.430) 55 (0.505) 10 (0.500)
TT 104 (0.355) 44 (0.512) 40 (0.367) 8 (0.400)
Adalimumab GG 3 (0.052) 1 (0.033) 1.67 0.22 (0.79) 4 (0.190) 0 (0.000) 1.42 0.65 (0.99) 1.61/1.61 0.19/0.19 (0.75/0.70)
GT 30 (0.517) 12 (0.400) 8 (0.381) 3 (0.500)
TT 25 (0.431) 17 (0.567) 9 (0.429) 3 (0.500)
Infliximab GG 11 (0.153) 2 (0.118) 1.34 0.48 (0.99) 3 (0.125) 2 (0.400) 0.40 0.26 (0.72) 1.05/0.90 0.89/0.85 (1.00/1.00)
GT 35 (0.486) 7 (0.412) 14 (0.583) 2 (0.400)
TT 26 (0.361) 8 (0.471) 7 (0.292) 1 (0.200)
Combined GG 52 (0.156) 7 (0.033) 1.74 0.0027 (0.0084) 21 (0.136) 4 (0.129) 1.01 0.98 (1.00) 1.50/1.39 0.010/0.22 (0.050/0.76)
GT 165 (0.493) 41 (0.483) 77 (0.500) 15 (0.484)
TT 118 (0.351) 49 (0.483) 56 (0.364) 12 (0.387)
Abbreviations: OR, odds ratio; SNP, single-nucleotide polymorphism; TNF, tumor necrosis factor.
Age at onset of disease is included as a covariate in the association model.
1Frequency and proportion of genotype among good and poor responders to drug therapy.
2OR for association of drug response and TNFAIP3 SNP in a logistic regression model using SNP allele dosages and age at onset.
3Nominal and corrected P-values (latter in parentheses) for association of drug response and TNFAIP3 genotype, with age at onset covariate.
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power of heterogeneity tests is known to be low when the
number of strata is small.
Other potential limitations of this study could also be
responsible for the different results for the two samples. We
combined skin and joint responses that were measured
individually in Toronto to approximate the undifferentiated
self-evaluated response for the Michigan sample. Moreover,
the response to medication in the Michigan cohort was
assessed retrospectively, which may introduce recall error
(although not recall bias, as it is unlikely that recall accuracy
is differentially affected by TNFAIP3 genotype). The similar
proportion of good responders in the two samples to each of
the anti-TNF therapies (Table 1) provides some confidence
that the two response metrics, although measured in different
ways, are reasonably similar. Nevertheless, the much higher
proportion of PsA in the Toronto sample could contribute to
the observed lack of association if the response of the joint
symptoms of people with PsA to anti-TNF therapy is more
poorly correlated with TNFAIP3 genotype than is response
of the skin symptoms of people with PsA or purely cutaneous
psoriasis. Supplementary Table S1 online compares skin-
only and joint-only responses in the Toronto sample.
Despite limited power, this analysis yields no indication that
joint symptoms are more poorly associated with TNFAIP3
genotype than are skin symptoms—for rs610604, the OR of
response of joint versus skin phenotypes is 1.17 versus 0.77
for etancercept and 1.08 versus 0.65 for all TNF blockers
combined. Unfortunately, a similar comparison in the
Michigan sample is not possible because this information
was not collected. In lieu of this, Supplementary Table S2
online compares response to TNF blockers in the Michigan
sample for people with PsA versus those with cutaneous
psoriasis. The strength of association with SNP rs610604 is
approximately equal for both phenotypes, being slightly
lower in PsA (OR¼1.67 vs. 1.77 for all TNF blockers
combined). Hence, neither sample supports the notion that
response of joint symptoms to anti-TNF therapy is less well
associated with TNFAIP3 genotype than is response of skin
symptoms, although the small sample sizes prevent any
definitive conclusions.
In conclusion, we demonstrate in this study that the G
allele of SNP rs610604 located in the TNFAIP3 gene and its
haplotype with the T allele of rs2230926 are markers of good
response to anti-TNF agents. The results of this study using a
limited sample set calls for confirmation by additional studies
with substantially larger number of samples, prospective
patient and physician evaluated responses, and gene and
protein expression levels measured before and after therapy.
Table 3. Association of TNFAIP3 haplotypes and a combined skin–joint response to TNF blockers for psoriasis
patients in the Michigan, Toronto, and combined samples
Michigan sample Toronto sample Combined analysis1
Drug Haplotype2 Freq3 OR4 Pnom
5 Pcorr
6 Freq3 OR4 Pnom
5 Pcorr
6 OR4 Pnom
5 Pcorr
6
Etanercept TG 0.409/0.269 1.92 0.00077 0.0038 0.381/0.350 1.10 0.83 1.00 1.71 0.0017 0.011
GT 0.025/0.040 0.55 0.18 0.82 0.037/0.025 1.60 0.44 1.00 0.67 0.36 0.96
TT 0.566/0.691 0.58 0.0039 0.023 0.583/0.625 0.85 0.71 1.00 0.63 0.0063 0.039
Omnibus — — 0.0030 0.0067 — — 0.81 0.98 — 0.0077 0.023
Adalimumab TG 0.303/0.232 1.63 0.26 0.87 0.381/0.250 1.42 0.67 1.00 1.57 0.23 0.83
GT 0.032/0.032 1.21 0.60 1.00 0.024/0.083 0.42 0.29 0.99 0.87 0.92 1.00
TT 0.665/0.736 0.63 0.24 0.84 0.595/0.667 0.86 0.85 1.00 0.67 0.25 0.86
Omnibus — — 0.36 0.86 — — 0.68 0.97 — 0.38 0.82
Infliximab TG 0.391/0.322 1.32 0.53 0.99 0.417/0.600 0.40 0.24 0.79 1.02 0.96 1.00
GT 0.013/0.056 0.21 0.14 0.76 0.021/0.000 N 0.73 1.00 0.29 0.17 0.87
TT 0.595/0.622 0.90 0.81 1.00 0.563/0.400 2.10 0.40 0.88 1.08 0.81 1.00
Omnibus — — 0.25 0.74 — — 0.27 0.79 — 0.41 0.91
Combined TG 0.404/0.279 1.82 0.0012 0.0060 0.386/0.371 1.01 0.98 1.00 1.55 0.0051 0.031
GT 0.025/0.031 0.73 0.49 0.99 0.032/0.032 1.11 0.61 1.00 0.81 0.63 1.00
TT 0.571/0.690 0.59 0.0034 0.016 0.581/0.597 0.98 0.93 1.00 0.67 0.0095 0.066
Omnibus — — 0.0055 0.014 — — 0.96 1.00 — 0.021 0.066
Abbreviations: OR, odds ratio; TNF, tumor necrosis factor.
Age at onset of disease is included as a covariate in the association model.
1Fixed effects meta-analysis.
2Haplotype for single-nucleotide polymorphisms rs2230926 and rs610604; omnibus refers to all haplotypes combined.
3Frequency of haplotypes in good responders and poor responders.
4Odds ratio for association of drug response and TNFAIP3 haplotype in a logistic regression model using haplotype dosages.
5Nominal P-value for association of drug response and TNFAIP3 haplotype.
6Corrected P-value for association of drug response and TNFAIP3 haplotype.
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Such efforts would also provide phenotype data and material
needed for a GWAS of anti-TNF agents. Further association
studies on TNFAIP3 and other genetically associated loci
could result in a panel of polymorphisms that can be
routinely typed in a clinical setting to help the physician
make an informed decision on administration of anti-TNF
therapy.
MATERIALS AND METHODS
Subjects
The Michigan sample included 433 patients with psoriasis who received
anti-TNF agents from 2005 to 2009 and completed a questionnaire
concerning their response to the drug therapy. The Toronto sample
consisted of 199 patients with PsV who received anti-TNF therapy
at Toronto Western Hospital, Center for Prognosis Studies in the
Rheumatic Diseases. A physician (dermatologist and/or rheumatologist)
diagnosed the presence of psoriasis and PsA in all patients. Only 3 of the
199 Toronto patients did not have cutaneous lesions.
All patients were of European Caucasian descent. Informed
consent was obtained from all subjects under protocols adherent to
the Declaration of Helsinki Principles, which were approved by the
Institutional Review Boards of the participating institutions.
Phenotypes
For the Michigan sample, response to treatment with anti-TNF drugs
(etanercept, adalimumab, and infliximab) was self-evaluated using a
0–5 visual analog scale, with 0 being not effective and 5 being very
effective. Responses were dichotomized as good if they scored from
3 to 5, and poor if they scored 0–2. For those patients treated with
more than one anti-TNF drug (17.7% of the sample received two and
5.5% all three drugs), a combined response to all TNF blockers was
computed as the mean of the raw 0–5 response for all drugs used by
the patient; the mean response was then dichotomized to responders
and nonresponders using a 2.5 threshold.
In Toronto, rheumatologists evaluated the response to treatment
for the same three anti-TNF drugs. Only response to the first anti-TNF
agent prescribed was considered. For skin symptoms, a 50% or
greater reduction from the patient’s baseline PASI was considered a
good response. For joint symptoms, a good response was defined as
a 50% or better decrease in the actively inflamed (swollen and/or
tender) joint count or 50% or better improvement in Bath Ankylosing
Spondylitis Disease Activity Index at 6 months from the initiation of
treatment. The skin and joint responses of the Toronto patients were
combined into a single metric for most of the analyses—if either or
both responses were good, the combined skin–joint response was
considered to be good. As all Toronto patients were evaluated for
response to the first anti-TNF drug, the combined response for all
TNF blockers was simply the combination of all single drug
responses across the sample.
Demographic data including age, sex, race, and history of psoriasis
and other autoimmune diseases in patients and family members were
recorded for both samples. BMI, fingernail involvement, age at onset,
and duration of psoriasis and PsA were also recorded.
Genotyping
In Ann Arbor, genomic DNA was prepared from peripheral blood
mononuclear cells or Epstein–Barr virus-immortalized lymphoblas-
toid cell lines, as previously described (Nair et al., 1995). In Toronto,
DNA was extracted from peripheral blood using a modified salting-
out procedure (Gentra Puregene Blood Kit, Qiagen, Valencia, CA).
The genotypes were determined by Taqman assay (Applied
Biosystems, Foster City, CA).
Statistical analysis
The Michigan and Toronto samples were compared for a variety of
epidemiological and phenotypic variables using two-sample tests for
the equality of the means. For variables expressed as a percentage,
Fisher’s exact test was used. All other variables except age were first
transformed using the optimal Box–Cox power transform (power of
0.5 for age at PsV onset and duration of PsV, 0.7 for age at PsA onset,
0.2 for duration of PsA, and 0.1 for BMI) in order to achieve near-
normality of the residuals of the appropriate regression model.
Means for age, age at onset of PsV, and age at onset of PsA were then
tested with the two-sample t-test for unequal variances. Means for
duration of PsV, duration of PsA, and BMI were tested with a
multiple regression model that included linear (duration PsA), linear
and quadratic (BMI), or linear, quadratic, and cubic (duration PsV)
terms for age and that used a Huber–White heteroscedasticity
consistent covariance matrix.
Data were analyzed for linear trend of association between drug
response and genotypes and haplotypes of two SNPs in TNFAIP3
using logistic regression, where drug response was coded as a binary
variable (0¼ poor, 1¼ good), and the genotype predictor variable
was expressed as the dosage of the SNP allele or two-SNP haplotype.
The association between drug response and several covariates
(worst-ever total body surface area, BMI, age at onset, and PsA) was
also tested with logistic regression. The Box-Tidwell procedure was
applied to association testing of total body surface area, BMI, and
age at onset to determine whether a power transformation was
necessary to achieve a linear relationship between the logit of drug
response and the covariate, which is an important assumption of
logistic regression. In all cases, the deviation between a model using
the optimal linearizing power transformation of the covariate and a
model using the untransformed covariate was nonsignificant, and
thus untransformed covariates were used in all tests. Age at onset,
the only covariate to show significant association with drug
response, was included in all tests assessing association between
drug response and genotypes and haplotypes of the two SNPs in
TNFAIP3. Interaction between age at onset and SNP genotype was
assessed with a likelihood ratio test applied to nested logistic
regression models with and without a multiplicative interaction
term. Conditional haplotype-based association testing was per-
formed by comparing the odds of disease for pairs of haplotypes that
have different alleles for the SNP under scrutiny but the same allele
for the other SNP.
For individual cohorts, nominal significance of association was
assessed using 100,000 random permutations of the drug response
variable. A special set of 100,000 restricted permutations of drug
response labels was generated to determine significance that was
corrected for multiple testing of 8 single marker tests (4 drug
treatments 2 SNPs), 12 individual haplotype tests (4 drugs
3 haplotypes), or 4 omnibus haplotype tests (4 drugs 1 omnibus
test). Responses for all SNP–drug combinations were permuted as
intact vectors to maintain all dependencies among responses, and
response vectors were permuted randomly within strata formed by
groups of patients receiving the same combination of drugs to ensure
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constant sample size among all permutations in the presence of
missing genotype data. The best association P-value among all tests
for each iteration of the permutation procedure was saved, the saved
P-values were sorted into ascending order, and the corrected P-value
determined as the fractional rank within this vector of the best
observed P-value across all tests.
Meta-analysis was used to test for association across both cohorts
combined. For single markers, standard fixed- and random-effects
models were used. Asymptotic P-values were reported for nominal
significance, and the restricted permutations generated for the
Michigan and Toronto samples were used to determine significance
corrected for multiple testing. For haplotypes, fixed-effects meta-
analysis of both cohorts was formulated as a logistic regression model
with sample cohort as an additional covariate, and permutations were
used to assess both nominal and corrected significance. Heterogeneity
of ORs between the two samples was tested with Cochran’sQ statistic
and the I2 heterogeneity index. All association analyses were carried
out with version 1.0.7 of PLINK (Purcell et al., 2007).
Power calculations were carried out with version 3.1.2 of
G*Power (Faul et al., 2007) using an exact unconditional test of
allelic association, which under Hardy–Weinberg equilibrium is
essentially equivalent to the permutational version of the logistic
regression test used in this study. Risk allele frequencies and the ratio
of good to poor responders in the underlying population were
estimated from the Toronto sample; the expected ORs for association
were estimated from the Michigan sample. A type I error rate of
0.021 was used to compute power of association tests that are
corrected for multiple testing, which is equivalent to a corrected
significance of 0.05 when testing single SNPs in the Toronto sample.
URLs
Plink software: http://pngu.mgh.harvard.edu/purcell/plink/.
G*Power software: http://www.psycho.uni-duesseldorf.de/aap/projects/
gpower/.
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